Zydus Cadila gets final approval from USFDA for Hepatitis B tablets
AHMEDABAD: Cadila Healthcare Ltd (Zydus Cadila) said here on Tuesday that it has received the final approval from the USFDA to market Entecavir tablets in the strengths of 0.5 mg and 1 mg.
The drug is used in the treatment of Hepatitis B virus infection and will be produced at the group’s formulations manufacturing facility at the Pharma SEZ in Ahmedabad, the company said in a release here.
The estimated sale for Entecavir tablets is $ 166.3 million per annum.
The group now has more than 120 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
AhmedabadapprovalCadila HealthcareEntecavirEntecavir Tabletshepatitis Bhepatitis B drugUSFDAZydus Cadila
Source : PTINext Story
NO DATA FOUND
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd